Screening for anal cancer after high-grade vulvar changes
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This trial checks whether anal cancer screening is useful for women age 40 and older who previously had high-grade vulvar pre-cancer (VIN 2/3) or vulvar cancer. It may help find serious problems earlier in people at higher risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 40 or older
- You have a prior diagnosis of VIN 2/3 or vulvar cancer
- You have NOT been diagnosed with other cancers (except skin basal cell, cervical cancer, or vulvar cancer)
- You are not living with HIV
- You are not taking medicines that weaken your immune system (immunosuppressants)
- You have not had a hysterectomy (surgery removing the uterus)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at ways to screen for anal cancer in people who are at higher risk, such as those with weakened immune systems or a history of abnormal cells in the lower genital tract. It aims to find better methods for early detection.
This study tests how well a special HPV test (called BD Onclarity™) can find anal cancer or precancer. It is for people at high risk or with known anal abnormalities, and aims to improve early detection.
This study is testing a new way to screen for anal cancer by looking at DNA methylation in cells collected from the anus. It may help people at higher risk for anal cancer find out earlier if they need further tests.
This trial checks whether tumor samples contain HPV DNA (genetic material from the HPV virus). The goal is to improve detection in anal and cervical cancers, especially in patients planning standard radiation treatment.
This trial tests two cervical screening approaches to find early signs of HPV-related changes. It may help by improving how results are sorted into “needs follow-up” versus “routine care,” especially for women with different HPV patterns.
This study looks at two tumor test results—HPV and p53—to help doctors decide how much tissue to remove during surgery for vulvar squamous cell carcinoma. It’s meant to reduce the risk of the cancer coming back while avoiding unnecessary removal when margins are only close.
Hear when a new Vulvar Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.